drugset / Trial / NCT01040728

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728

Phase 3 Completed 122 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Timeline

Start
2010-01
Primary completion
2011-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled